Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: July 8, 2013
Last updated: September 22, 2014
Last verified: September 2014
The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.
Benign Prostatic Hyperplasia (BPH)
Device: Vortx Rx - Histotripsy BPH Device
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
Primary Outcome Measures:
- Safety of the Vortx Rx for treatment of symptomatic BPH [ Time Frame: 1 Day, 1, 3 and 6 months ] [ Designated as safety issue: Yes ]
- Record and report all adverse events.
- Determine rate of occurrence of adverse events, serious adverse events and device-related adverse events as a measure of safety and as factors used to determine study success.
Secondary Outcome Measures:
- Initial prostate histotripsy treatment efficacy [ Time Frame: 1, 3 and 6 months ] [ Designated as safety issue: No ]
- Change in LUTS as measured by International Prostate Symptom Score (IPSS), uroflow (Qmax), post-void residual (PVR). Each to be measured at 1, 3 and 6 months.
- Change in prostate parenchymal volume (TRUS and prostate-specific antigen [PSA]). TRUS to be performed at end of treatment and at 6 months post-treatment. PSA to be tested 6 months post-treatment.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2015 (Final data collection date for primary outcome measure)
Experimental: Vortx Rx - Histotripsy BPH Device
The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
Device: Vortx Rx - Histotripsy BPH Device
Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
- HistoSonics Histotripsy BPH device
- Vortx Rx
Prospective, single-arm study
|Ages Eligible for Study:
||50 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Diagnosis of BPH and eligible for endoscopic BPH surgery including TURP, PVP, electrovaporization.
- Prostate volumes 30 - 80 gm based on transrectal ultrasound
- Men ≥ 50 years of age
- IPSS symptom score > 15 and IPSS bother score > 2 (see Appendix B for IPSS questionnaire)
- Baseline peak flow rate Qmax < 12 cc/s on two separate occasions with voided volume at least 150 cc
- History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, urethral strictures/bladder neck contracture (BNC), renal insufficiency (i.e. creatinine > 1.4)
- Neurogenic bladder, Parkinson's disease
- Prior treatment for urinary incontinence
- Micturition frequency AND urgency. Micturition frequency defined as > 8 micturitions per 24 hours as assessed by a thorough subject history including the question: "On average, how many times do you void during a 24 hour period? // < 4, 5-7, 8 or more." Urgency defined as an uncontrollable urge to void that occurs > 3 per 24 hours as assessed through the subject history/question: "On average, how many times a day do you have an uncontrollable urgency to void? // 0, 1-2, 3 or more?"
- Intravesical prostate lobe protrusion > 1 cm on TRUS. Note: this is distinct from lateral lobes protruding up to the bladder such as an intravesical protrusion without median lobe
- Active UTI (i.e. must have a screening urinalysis without signs of infection or a negative urine culture)
- PVR > 250 at time of enrollment or catheter dependent bladder drainage
- History of chronic prostatitis within the last 5 years
- Not able to temporarily discontinue aspirin, Coumadin, Plavix and any other anticoagulant at least seven days prior to the time of treatment
- History of known bleeding disorders (e.g. von Willebrand disease [VWD]) and subjects determined to have a bleeding disorder by prothrombin time (PT) and partial thromboplastin time (PTT) tests.
- Prior BPH prostate procedures (e.g. TUMT, TUNA, water induced thermotherapy [WIT], TURP, PVP)
- Men with confirmed or suspected malignancy of the prostate based on a digital rectal exam (DRE), prostate biopsy or PSA > 10 ng/mL. Men with free PSA < 25% and PSA between 2.5 and 10 ng/mL may only be enrolled after a negative biopsy. If a prior prostate biopsy was performed within one year of enrollment and was negative for cancer, repeat biopsy is not required if in the investigator's judgment there is no clinical evidence to support biopsy reassessment. If a biopsy is required, the subject shall have a six-week waiting period between the biopsy and histotripsy treatment, if he is otherwise deemed eligible to participate in the study.
- Men interested in future fertility
- Declines or unable to provide informed consent
- Life expectancy estimated to be less than one year
- Unable or unwilling to complete all required questionnaires and follow-up assessments
- In the opinion of the investigator, it is not in the subject's best interest to participate in the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01896973
|Univerisity of Michigan
|Ann Arbor, Michigan, United States, 48109 |
|ProMedica Parkway Surgery Center
|Toledo, Ohio, United States, 43606 |
||Timonthy Schuster, MD
||ProMedica Parkway Surgery Center
||John Wei, MD
||University of Michigan
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 8, 2013
||September 22, 2014
||United States: Food and Drug Administration
United States: Institutional Review Board
Keywords provided by HistoSonics, Inc.:
Benign Prostatic Hyperplasia
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 03, 2015
Genital Diseases, Male